Lipe & Dalton grew its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 8.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,209 shares of the biopharmaceutical company’s stock after purchasing an additional 5,030 shares during the quarter. Bristol-Myers Squibb comprises approximately 2.4% of Lipe & Dalton’s portfolio, making the stock its 16th largest holding. Lipe & Dalton’s holdings in Bristol-Myers Squibb were worth $3,745,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares in the last quarter. Keel Point LLC lifted its stake in Bristol-Myers Squibb by 0.3% in the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 18 shares in the last quarter. Staley Capital Advisers Inc. lifted its stake in Bristol-Myers Squibb by 0.3% in the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock worth $379,000 after purchasing an additional 24 shares in the last quarter. Shayne & CO. LLC lifted its stake in Bristol-Myers Squibb by 0.6% in the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 24 shares in the last quarter. Finally, Greenleaf Trust raised its position in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after buying an additional 39 shares during the period. 69.51% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb Company (NYSE BMY) opened at $61.25 on Wednesday. The company has a market cap of $99,822.34, a price-to-earnings ratio of 20.60, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 EPS. sell-side analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 61.42%.
COPYRIGHT VIOLATION NOTICE: This story was reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://weekherald.com/2017/11/15/lipe-dalton-grows-holdings-in-bristol-myers-squibb-company-bmy.html.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.23% of the company’s stock.
Several analysts have recently commented on BMY shares. Vetr lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price target on the stock. in a research report on Tuesday, July 25th. BMO Capital Markets reaffirmed an “underperform” rating and set a $47.00 price target (down previously from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Piper Jaffray Companies set a $60.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, July 27th. Leerink Swann reduced their price target on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a research report on Friday, July 28th. Finally, BidaskClub lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $64.93.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.